With the flow of initial public offerings frustratingly sluggish and a tight financing environment, biopharma companies are looking for advice on other ways to bring in funding capital or explore business development options. In challenging times, experts agree it can be good to fall back on best practices.
Key Takeaways
-
Panelists at the recent LSX USA meeting offered advice to biotechs on how to approach partnering with deep-pocketed firms.
-
Suggestions included making enduring relationships and bringing strong data packages to the deal table, but also some more targeted advice to companies who may have to promote limited or mixed datasets
At the LSX World Congress USA, held 11-12 September in Boston, speakers from biopharma and other life sciences firms were asked to share their best ideas for how to succeed in business development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
